Compare ICCC & BENF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCC | BENF |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | United States |
| Employees | N/A | 55 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.5M | 53.0M |
| IPO Year | 1995 | N/A |
| Metric | ICCC | BENF |
|---|---|---|
| Price | $6.43 | $3.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.2K | ★ 21.8K |
| Earning Date | 03-04-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.33 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $26,493,169.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $30.01 |
| P/E Ratio | $32.60 | ★ N/A |
| Revenue Growth | ★ 51.64 | N/A |
| 52 Week Low | $4.52 | $0.22 |
| 52 Week High | $7.60 | $9.96 |
| Indicator | ICCC | BENF |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 36.05 |
| Support Level | $6.20 | $3.16 |
| Resistance Level | $6.79 | $4.84 |
| Average True Range (ATR) | 0.18 | 0.26 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 39.26 | 7.79 |
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.